AGMB

AgomAb Therapeutics NV

Price Chart

Latest Quote

$12.04

-0.28 (-2.27%)

Current Price

Previous Close	$12.32
Open	$12.00
Day High	$12.67
Day Low	$11.56
Volume	57,391

Fetched: 2026-07-18T00:58:28

Stock Information

Note: Financial values converted from EUR to USD

Shares Outstanding	49.25M
Total Debt	$1.44M
Cash Equivalents	$133.36M
Net Income	$-88.70M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$592.95M
EPS (TTM)	$-1.46
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$777.37M
Income	$-88.70M
Book/sh	$-3.90
Cash/sh	$2.37
Employees	62

Financial Ratios

Quick Ratio	6.49
Current Ratio	6.52
Debt/Eq	0.96

Returns & Margins

ROA	-20.58%
ROE	-39.22%

Ownership

Insider Ownership	5.90%
Institutional Ownership	48.45%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-6.03
P/B	-3.09

Analyst Data

Recommendation	none
Target Price	$32.75

Technical Indicators

SMA20	$12.85
SMA50	$11.73
RSI	44.08
ATR	1.6250

Shares Float	16.41M
Short Float	3.05%
Short Ratio	9.50
Rel Volume	0.52

Performance History

Week	-7.95%
Month	+20.40%
Quarter	+7.50%
YTD	-17.82%
10 Years	-17.82%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$12.04	57,400
2026-07-16	$12.32	66,400
2026-07-15	$12.63	143,000
2026-07-14	$12.04	49,000
2026-07-13	$12.31	116,200
2026-07-10	$13.08	47,200
2026-07-09	$13.03	54,300
2026-07-08	$12.74	45,500
2026-07-07	$13.28	97,700
2026-07-06	$13.52	107,100
2026-07-02	$12.65	38,900
2026-07-01	$11.87	166,700
2026-06-30	$12.98	264,200
2026-06-29	$17.82	200,300
2026-06-26	$13.81	96,400
2026-06-25	$13.43	93,900
2026-06-24	$12.68	199,300
2026-06-23	$11.94	54,300
2026-06-22	$11.84	126,000
2026-06-18	$10.98	189,000

About AgomAb Therapeutics NV

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

📰 Latest News

Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?

Insider Monkey • 2026-07-02T20:06:30Z

Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease

MT Newswires • 2026-06-23T21:32:29Z

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Insider Monkey • 2026-04-12T18:46:47Z

European Equities Traded in the US as American Depositary Receipts Higher Wednesday

MT Newswires • 2026-02-18T16:15:13Z

Agomab indicated to open at $15.50, IPO priced at $16

TipRanks • 2026-02-07T15:55:19Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$68,642	$76,650	$35,465	$51,482
Total Expenses	$67,812,603	$54,937,647	$35,682,414	$25,894,061
Rent Expense Supplemental	$241,391	$156,733	$203,638	$139,572
Other Income Expense	$-5,511,955	$705,869	$21,703,465	$13,503,031
Other Non Operating Income Expenses	$-5,556,572	$970,141	$21,695,457	$13,601,418
Net Non Operating Interest Income Expense	$1,768,676	$1,305,343	$240,247	$28,601
Total Other Finance Cost	$3,432	$11,440	$4,576	$1,144
Interest Expense Non Operating	$68,642	$76,650	$35,465	$51,482
Operating Expense	$67,812,603	$54,937,647	$35,682,414	$25,894,061
Other Operating Expenses	$-2,151,928	$-1,171,491	$-1,013,614	$-1,013,614
General And Administrative Expense	$14,382,793	$11,236,700	$6,860,771	$5,136,712
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Net Interest Income	$1,768,676	$1,305,343	$240,247	$28,601
Interest Income	$1,840,750	$1,393,433	$280,288	$81,226
Normalized Income	$-71,600,499	$-52,732,808	$-13,038,153	$-9,254,707
Net Income From Continuing And Discontinued Operation	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Total Operating Income As Reported	$-67,812,603	$-54,937,647	$-35,682,414	$-25,894,061
Net Income Common Stockholders	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Net Income	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Net Income Including Noncontrolling Interests	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Net Income Continuous Operations	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Pretax Income	$-71,555,882	$-52,926,436	$-13,738,702	$-12,362,429
Interest Income Non Operating	$1,840,750	$1,393,433	$280,288	$81,226
Operating Income	$-67,812,603	$-54,937,647	$-35,682,414	$-25,894,061
Depreciation Amortization Depletion Income Statement	$250,543	$355,795	$113,259	$26,313
Depreciation And Amortization In Income Statement	$250,543	$355,795	$113,259	$26,313
Per Share
Diluted EPS	-	$-1.46	$-0.36	$-0.26
Basic EPS	-	$-1.46	$-0.36	$-0.26
Other
Tax Effect Of Unusual Items	$0	$-66,068	$400	$-38,371
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-71,281,314	$-52,229,719	$-13,597,986	$-12,186,248
Total Unusual Items	$44,617	$-264,272	$8,008	$-98,387
Total Unusual Items Excluding Goodwill	$44,617	$-264,272	$8,008	$-98,387
Reconciled Depreciation	$250,543	$355,795	$113,259	$26,313
EBITDA (Bullshit earnings)	$-71,236,697	$-52,493,991	$-13,589,978	$-12,284,635
EBIT	$-71,487,240	$-52,849,785	$-13,703,237	$-12,310,948
Diluted NI Availto Com Stockholders	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Tax Provision	$0	$4,576	$-708,157	$-3,047,706
Gain On Sale Of Security	$44,617	$-264,272	$8,008	$-98,387
Other Taxes	$-585,745	$-455,325	$-378,675	$-473,630
Research And Development	$55,916,940	$44,971,969	$30,100,673	$22,218,280
Selling General And Administration	$14,382,793	$11,236,700	$6,860,771	$5,136,712
Other Gand A	$3,722,686	$5,240,819	$2,675,895	$1,845,327
Rent And Landing Fees	$241,391	$156,733	$203,638	$139,572
Salaries And Wages	$10,418,716	$5,839,149	$3,981,238	$3,151,813
Diluted Average Shares	-	$41,456,100	$41,456,100	$41,456,100
Basic Average Shares	-	$41,456,100	$41,456,100	$41,456,100

Fetched: 2026-07-05

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$116,897,374	$182,312,082	$140,387,820	$42,931,012
Total Assets	$175,844,859	$236,080,527	$195,926,085	$115,541,694
Total Non Current Assets	$37,145,633	$37,195,971	$36,363,114	$34,218,051
Non Current Accounts Receivable	$2,459,673	$2,044,388	$1,651,985	$1,272,166
Investmentin Financial Assets	$12,584	$13,728	$16,016	$16,016
Goodwill And Other Intangible Assets	$32,858,939	$32,858,939	$32,858,939	$32,858,939
Other Intangible Assets	$23,006,520	$23,006,520	$23,006,520	$23,006,520
Current Assets	$138,699,226	$198,884,556	$159,562,970	$81,323,643
Current Deferred Assets	$729,894	$305,457	$137,284	$97,243
Receivables	$4,673,378	$2,424,208	$19,392,517	$3,809,633
Other Receivables	$4,427,411	$1,925,409	$19,048,163	$3,568,241
Taxes Receivable	$228,807	$435,877	$168,173	$83,514
Notes Receivable	$17,161	$62,922	$176,181	$157,877
Cash Cash Equivalents And Short Term Investments	$133,295,954	$196,154,891	$140,032,025	$77,416,767
Cash And Cash Equivalents	$98,865,113	$196,154,891	$140,032,025	$31,655,415
Cash Equivalents	$0	$165,884,901	$0	-
Cash Financial	$98,865,113	$30,269,990	$140,032,025	$31,655,415
Other Non Current Assets	-	-	$-1,144	-
Other Current Assets	-	-	$1,144	-
Debt
Total Debt	$1,434,618	$1,767,532	$1,853,335	$70,930
Long Term Debt And Capital Lease Obligation	$1,149,754	$1,455,211	$1,646,265	$41,185
Current Debt And Capital Lease Obligation	$284,864	$312,321	$207,070	$29,745
Long Term Debt	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$26,088,547	$20,909,506	$22,679,326	$39,751,742
Total Non Current Liabilities Net Minority Interest	$4,822,102	$10,469,053	$10,226,518	$5,755,634
Other Non Current Liabilities	$3,672,348	$9,013,842	$8,580,254	$5,002,860
Current Liabilities	$21,266,444	$10,440,452	$12,452,808	$33,996,108
Other Current Liabilities	$7,468,253	-	$1,403,729	$26,677,724
Current Deferred Liabilities	$1,671,433	$916,371	$1,351,104	$2,031,804
Payables And Accrued Expenses	$11,841,894	$9,211,760	$9,490,904	$5,256,835
Payables	$9,031,003	$7,011,783	$8,044,846	$4,533,806
Total Tax Payable	$304,313	$202,494	$231,095	$76,650
Accounts Payable	$8,726,690	$6,809,289	$7,813,751	$4,457,156
Non Current Deferred Liabilities	-	-	$0	$711,589
Non Current Deferred Taxes Liabilities	-	-	$0	$711,589
Equity
Common Stock Equity	$149,756,312	$215,171,021	$173,246,759	$75,789,951
Total Equity Gross Minority Interest	$149,756,312	$215,171,021	$173,246,759	$75,789,951
Stockholders Equity	$149,756,312	$215,171,021	$173,246,759	$75,789,951
Other Equity Interest	$15,875,757	$9,749,456	$8,526,484	$6,055,371
Gains Losses Not Affecting Retained Earnings	$-1,106,281	$-1,105,137	$-957,556	$-439,309
Other Equity Adjustments	$-1,106,281	$-1,105,137	$-957,556	$-439,309
Retained Earnings	$-207,886,958	$-136,347,092	$-83,321,126	$-70,290,581
Other
Ordinary Shares Number	$55,756,522	$55,756,522	$55,756,522	$55,756,522
Share Issued	$55,756,522	$55,756,522	$55,756,522	$55,756,522
Tangible Book Value	$116,897,374	$182,312,082	$140,387,820	$42,931,012
Invested Capital	$149,756,312	$215,171,021	$173,246,759	$75,789,951
Working Capital	$117,432,782	$188,444,104	$147,110,162	$47,327,534
Capital Lease Obligations	$1,434,618	$1,767,532	$1,853,335	$70,930
Total Capitalization	$149,756,312	$215,171,021	$173,246,759	$75,789,951
Additional Paid In Capital	$87,671,886	$87,671,886	$49,123,667	$14,149,410
Capital Stock	$255,201,908	$255,201,908	$199,875,289	$126,315,060
Common Stock	$255,201,908	$255,201,908	$199,875,289	$126,315,060
Long Term Capital Lease Obligation	$1,149,754	$1,455,211	$1,646,265	$41,185
Current Deferred Revenue	$1,671,433	$916,371	$1,351,104	$2,031,804
Current Capital Lease Obligation	$284,864	$312,321	$207,070	$29,745
Current Accrued Expenses	$2,810,891	$2,199,977	$1,446,059	$723,029
Investments And Advances	$12,584	$13,728	$16,016	$16,016
Available For Sale Securities	$12,584	$13,728	$16,016	$16,016
Goodwill	$9,852,419	$9,852,419	$9,852,419	$9,852,419
Net PPE	$1,814,438	$2,278,915	$1,837,318	$70,930
Accumulated Depreciation	$-940,396	$-487,358	$-139,572	$-26,313
Gross PPE	$2,754,833	$2,766,274	$1,976,890	$97,243
Leases	$410,708	$410,708	$0	-
Other Properties	$11,440	$11,440	-	-
Machinery Furniture Equipment	$788,239	$835,145	$367,235	$30,889
Buildings And Improvements	$1,544,446	$1,508,981	$1,609,656	$66,354
Properties	$0	$0	$0	$0
Other Short Term Investments	$34,430,841	$0	$0	$45,761,352

Fetched: 2026-07-05

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-59,198,029	$-54,345,038	$-28,134,079	$-21,698,889
Operating Activities
Operating Cash Flow	$-59,193,453	$-53,572,815	$-28,134,079	$-21,698,889
Cash Flow From Continuing Operating Activities	$-59,193,453	$-53,573,959	$-28,134,079	$-21,698,889
Operating Gains Losses	$65,210	$264,272	-	-
Investing Activities
Capital Expenditure	$-4,576	$-772,223	-	-
Investing Cash Flow	$-37,757,692	$-772,223	$45,761,352	$-51,007,891
Cash Flow From Continuing Investing Activities	$-37,757,692	$-772,223	$45,761,352	$-51,007,891
Financing Activities
Issuance Of Capital Stock	$0	$111,034,200	$91,375,124	$43,913,737
Financing Cash Flow	$-386,683	$110,698,999	$90,749,337	$43,052,280
Cash Flow From Continuing Financing Activities	$-386,683	$110,700,143	$90,749,337	$43,052,280
Net Common Stock Issuance	$0	$111,034,200	$91,375,124	$43,913,737
Common Stock Issuance	$0	$111,034,200	$91,375,124	$43,913,737
Net Other Financing Charges	-	$-148,724	$-511,383	$-41,185
Other
Repayment Of Debt	$-386,683	$-186,478	$-114,403	$-820,272
End Cash Position	$98,865,113	$196,154,891	$140,032,025	$31,655,415
Beginning Cash Position	$196,154,891	$140,032,025	$31,655,415	$61,309,915
Effect Of Exchange Rate Changes	$51,482	$-233,383	$0	$0
Changes In Cash	$-97,341,260	$56,356,249	$108,376,610	$-29,654,500
Net Issuance Payments Of Debt	$-386,683	$-186,478	$-114,403	$-820,272
Net Long Term Debt Issuance	$-386,683	$-186,478	$-114,403	$-820,272
Long Term Debt Payments	$-386,683	$-186,478	$-114,403	$-820,272
Net Investment Purchase And Sale	$-34,321,014	$0	$45,761,352	$-45,761,352
Purchase Of Investment	$-34,321,014	-	-	-
Net Business Purchase And Sale	$-3,432,101	$0	$0	$-5,246,539
Purchase Of Business	$-3,432,101	$0	$0	$-5,246,539
Net PPE Purchase And Sale	$-4,576	$-772,223	$0	-
Purchase Of PPE	$-4,576	$-772,223	$0	-
Taxes Refund Paid	$0	$-4,576	$-3,432	$-2,288
Interest Received Cfo	$1,855,623	$1,265,301	$280,288	$82,370
Interest Paid Cfo	$-78,938	$-11,440	$-22,881	$-50,337
Change In Working Capital	$464,478	$-1,466,651	$4,711,131	$1,611,944
Change In Other Working Capital	$854,593	$-451,893	$-663,540	$1,655,417
Change In Other Current Assets	$-3,088,891	$-751,630	$1,157,762	$-3,419,517
Change In Payables And Accrued Expense	$2,698,776	$-263,128	$4,216,909	$3,376,044
Change In Payable	$2,698,776	$-263,128	$4,216,909	$3,376,044
Other Non Cash Items	$-1,767,532	$-1,304,199	$-248,255	$69,786
Stock Based Compensation	$6,126,301	$1,225,260	$2,469,969	$2,527,171
Unrealized Gain Loss On Investment Securities	$5,446,745	$-970,141	$-21,695,457	$-13,601,418
Deferred Tax	$0	$4,576	$-708,157	$-3,047,706
Deferred Income Tax	$0	$4,576	$-708,157	$-3,047,706
Depreciation Amortization Depletion	$250,543	$355,795	$113,259	$26,313
Depreciation And Amortization	$250,543	$355,795	$113,259	$26,313
Net Foreign Currency Exchange Gain Loss	$65,210	$264,272	$0	-
Net Income From Continuing Operations	$-71,555,882	$-52,931,012	$-13,030,545	$-9,314,723
Sale Of Investment	-	$0	$45,761,352	-
Change In Prepaid Assets	-	$-451,893	$-663,540	$1,655,417
Amortization Cash Flow	-	$0	$0	$0
Amortization Of Intangibles	-	$0	$0	$0
Depreciation	-	$355,795	$113,259	$26,313

Fetched: 2026-07-05